Aarhus Universitets segl

English

Du er her: AU » Om AU » Organisation » Julie Schmidt » Publikationer » Pan-cancer analysis of pre-diagnostic blood metabolite co...

Om AU

Julie Schmidt

Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European Prospective Investigation into Cancer and Nutrition

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

DOI

  • Marie Breeur, International Agency for Research on Cancer, Frankrig
  • Pietro Ferrari, International Agency for Research on Cancer, Frankrig
  • Laure Dossus, International Agency for Research on Cancer, Frankrig
  • Mazda Jenab, International Agency for Research on Cancer, Frankrig
  • Mattias Johansson, International Agency for Research on Cancer, Frankrig
  • Sabina Rinaldi, International Agency for Research on Cancer, Frankrig
  • Ruth C Travis, University of Oxford, Storbritannien
  • Mathilde His, International Agency for Research on Cancer, Frankrig
  • Tim J Key, University of Oxford, Storbritannien
  • Julie A Schmidt
  • Kim Overvad
  • Anne Tjønneland, Kræftens Bekæmpelse, Danmark
  • Cecilie Kyrø, Kræftens Bekæmpelse, Danmark
  • Joseph A Rothwell, Universite Paris-Saclay, Frankrig
  • Nasser Laouali, Universite Paris-Saclay, Frankrig
  • Gianluca Severi, Universite Paris-Saclay, Frankrig
  • Rudolf Kaaks, German Cancer Research Center, Tyskland
  • Verena Katzke, German Cancer Research Center, Tyskland
  • Matthias B Schulze, German Institute of Human Nutrition (DIfE)
    • ,
  • Fabian Eichelmann, German Center for Diabetes Research, German Institute of Human Nutrition (DIfE) , Tyskland
  • Domenico Palli, Institute for the Study and Prevention of Cancer (ISPRO), Italien
  • Sara Grioni, IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano, Italien
  • Salvatore Panico, University of Naples Federico II, Italien
  • Rosario Tumino, Hyblean Association for Epidemiological Research (AIRE-ONLUS), Italien
  • Carlotta Sacerdote, Azienda Ospedaliera - Universitaria Città della Salute e della Scienza di Torino, Italien
  • Bas Bueno-de-Mesquita, National Institute for Public Health and the Environment (RIVM), Holland
  • Karina Standahl Olsen, UiT The Arctic University of Norway, Norge
  • Torkjel Manning Sandanger, UiT The Arctic University of Norway, Norge
  • Therese Haugdahl Nøst, UiT The Arctic University of Norway, Norge
  • J Ramón Quirós, Public Health and Health Planning Directorate, Spanien
  • Catalina Bonet, Catalan Institute of Oncology - ICO, Spanien
  • Miguel Rodríguez Barranco, Escuela Andaluza de Salud Publica, CIBER - Center for Biomedical Research Network, Spanien
  • María-Dolores Chirlaque, CIBER - Center for Biomedical Research Network, University of Murcia, Spanien
  • Eva Ardanaz, CIBER - Center for Biomedical Research Network, Universidad Pública de Navarra, Navarra Institute for Health Research (IdiSNA), Spanien
  • Malte Sandsveden, Lund University, Sverige
  • Jonas Manjer, Lund University, Sverige
  • Linda Vidman, Umeå University, Sverige
  • Matilda Rentoft, Umeå University, Sverige
  • David Muller, Imperial College London, Storbritannien
  • Kostas Tsilidis, Imperial College London, Storbritannien
  • Alicia K Heath, Imperial College London, Storbritannien
  • Hector Keun, Imperial College London, Storbritannien
  • Jerzy Adamski, Helmholtz Zentrum München - German Research Center for Environmental Health, National University of Singapore, University of Ljubljana, Tyskland
  • Pekka Keski-Rahkonen, International Agency for Research on Cancer, Frankrig
  • Augustin Scalbert, International Agency for Research on Cancer, Frankrig
  • Marc J Gunter, International Agency for Research on Cancer
    • ,
  • Vivian Viallon, International Agency for Research on Cancer, Frankrig

BACKGROUND: Epidemiological studies of associations between metabolites and cancer risk have typically focused on specific cancer types separately. Here, we designed a multivariate pan-cancer analysis to identify metabolites potentially associated with multiple cancer types, while also allowing the investigation of cancer type-specific associations.

METHODS: We analysed targeted metabolomics data available for 5828 matched case-control pairs from cancer-specific case-control studies on breast, colorectal, endometrial, gallbladder, kidney, localized and advanced prostate cancer, and hepatocellular carcinoma nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. From pre-diagnostic blood levels of an initial set of 117 metabolites, 33 cluster representatives of strongly correlated metabolites and 17 single metabolites were derived by hierarchical clustering. The mutually adjusted associations of the resulting 50 metabolites with cancer risk were examined in penalized conditional logistic regression models adjusted for body mass index, using the data-shared lasso penalty.

RESULTS: Out of the 50 studied metabolites, (i) six were inversely associated with the risk of most cancer types: glutamine, butyrylcarnitine, lysophosphatidylcholine a C18:2, and three clusters of phosphatidylcholines (PCs); (ii) three were positively associated with most cancer types: proline, decanoylcarnitine, and one cluster of PCs; and (iii) 10 were specifically associated with particular cancer types, including histidine that was inversely associated with colorectal cancer risk and one cluster of sphingomyelins that was inversely associated with risk of hepatocellular carcinoma and positively with endometrial cancer risk.

CONCLUSIONS: These results could provide novel insights for the identification of pathways for cancer development, in particular those shared across different cancer types.

OriginalsprogEngelsk
Artikelnummer351
TidsskriftBMC Medicine
Vol/bind20
Nummer1
Antal sider17
ISSN1741-7015
DOI
StatusUdgivet - dec. 2022

Bibliografisk note

© 2022. The Author(s).

Se relationer på Aarhus Universitet Citationsformater

ID: 286291341